DVX 201
Alternative Names: DVX-201Latest Information Update: 28 Sep 2024
At a glance
- Originator Deverra Therapeutics
- Developer Deverra Therapeutics; Duke University
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- No development reported COVID-19 pneumonia
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in COVID-19 pneumonia in USA (Parenteral, Infusion)
- 04 Jun 2024 Deverra Therapeutics, in collaboration with Duke University completes a phase I trial in Myelodysplastic syndromes and Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (NCT04901416)
- 08 Jan 2024 Coeptis plans a Phase II trial in Respiratory tract infections